Ondine Biomedical Inc. (AIM:OBI)
10.50
-0.50 (-4.76%)
Jun 13, 2025, 4:35 PM GMT+1
Ondine Biomedical Company Description
Ondine Biomedical Inc., a life-sciences company, engages in the development and commercialization of treat infections, including those caused by drug-resistant pathogens antimicrobial therapies in Canada and internationally.
Its main product Steriwave, enables rapid elimination of pathogens associated with healthcare-associated infections.
In addition, the company offers pipeline products on platform which includes burns, ventilator tube, and sinus; and Serious, Chronic wounds, Chronic sinusitis, Ventilator-associated pneumonia VAP, Central line bloodstream infections CLABSI, as well as Catheter-associated urinary tract infection CAUTI.
The company was incorporated in 1996 and is headquartered in Vancouver, Canada.
Ondine Biomedical Inc.
Country | Canada |
Founded | 1996 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 18 |
CEO | Carolyn Cross |
Contact Details
Address: 1100 Melville Street Vancouver, British Columbia V6E 4A6 Canada | |
Phone | 604 669 0555 |
Website | ondinebio.com |
Stock Details
Ticker Symbol | OBI |
Exchange | London Stock Exchange AIM |
Fiscal Year | January - December |
Reporting Currency | CAD |
ISIN Number | CA68234M2058 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Carolyn Cross | Chief Executive Officer |
Alan Thomas | Chief Financial Officer |